AGP Executive Report
Last update: 2 hours agoDrug Costs: A German health-insurer study says a 25% rise in German medicine prices would add about €5.5 billion to annual drug spending, while cutting projected US Medicaid savings by roughly $300 million. Bayer: The German company won US approval for asundexian to prevent another stroke; a trial found a 26% reduction in recurrent stroke risk when added to standard antiplatelet treatment, without more serious bleeding. Hearing Care: A study of 249 cochlear implant users led by Hannover Medical School researchers found standard speech tests don’t reliably reflect patients’ perceived sound quality, underscoring the value of measuring both. Mental Health: Ulm University researchers tracking psychiatric inpatients receiving dialectical behavior therapy found dissociation, emotional instability and severe inner tension eased over the first three weeks. Dialysis Competition: Washington state has sued US providers DaVita and Germany’s Fresenius, alleging physician noncompete agreements restrict competition and patient choice; Fresenius had not commented.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
